The global tumor necrosis factor inhibitor drugs market size was valued at USD 40.4 billion in 2018 and is estimated to expand at a CAGR of 0.5% over the forecast period. The growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF).
TNF inhibitors are used to suppress the inflammatory response caused by TNF cytokines and hence are used for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer among others. The role of TNF inhibitors in the treatment of metastatic melanomas and locally advanced soft tissue sarcomas is under investigation.
The biologics in TNF inhibitor market face a direct internal threat from biosimilars. Loss of patent exclusivities in various regions pave the way for biosimilars. In addition, the market is engaged in an intense competitive rivalry with Interleukin (IL) inhibitors. IL inhibitors have been proven to have improved safety and efficacy profiles and demonstrate superior results in several head-to-head clinical trials.
A significant paradigm shift in the treatment of autoimmune diseases, driven by the targeted action of biologics and the emergence of biosimilars has been observed. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.
Humira led the product segment in 2018, capturing nearly half the revenue share. Humira generated USD 19.9 billion in 2018 and continues to be one of the top-selling pharmaceutical products in the world. Although Humira’s patent expired in Europe in 2018, the product retains its patent exclusivity in U.S. until 2023. The loss of patent exclusivity is likely to result in declining sales; however, Humira is projected to be at top of the TNF inhibitor products through to 2026.
The wave of biosimilars poses a serious threat to biologics, supported by their cost-effectiveness and comparable results in head-to-head clinical trials. Several biosimilar versions of Humira, Enbrel, and Remicade have been launched. Some of the key biosimilar products included in this research are Erelzi, Inflectra/Remsima, Cyltezo, Renflexis/Flixabi, Ifixi/Zessly, Hyrimoz, and Amjevita/Amgevita.
Autoimmune disease segment accounts for a majority of the market share, although the medicines are being tested for other indications, such as cancer. Rheumatoid arthritis led the application segment in 2018, capturing more than 17% of the overall revenue share. The segment is driven by a high treatment rate and product penetration for the treatment of rheumatoid arthritis.
Psoriasis and psoriatic arthritis are estimated to be the fastest growing application segments through the forecast period. Psoriasis market is driven by increasing disease prevalence, consumer awareness supported by awareness campaigns held by several public and private organizations, and favorable reimbursement policies.
TNF inhibitor drugs are commercialized through three sales channels, namely, hospital pharmacies, specialty pharmacies, and online pharmacies. Hospital pharmacies accounted for the largest market share in 2018, majorly driven by the high patient turnover in hospitals.
Most biologics and biosimilars are sold at specialty pharmacies, rather than retail pharmacies. One of the major advantages offered by specialty pharmacies is that they provide disease-specific care plans, customized for each patient, thus addressing financial constraints as well as delivering better outcomes.
North America led the regional landscape in 2018, owing to strong commercial sales of TNF inhibitors in U.S. Some of the other factors contributing to the growth include the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool.
Asia Pacific is estimated to be one of the fastest growing regions, over the forecast period. The trend of biosimilars in the emerging markets, such as China, India, and South Korea, is a key regional growth driver. In addition, the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely to contribute to the regional demand.
Some key players include AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; UCB S.A.; Novartis International AG; Pfizer, Inc.; and Merck & co., Inc. Strategic initiatives including mergers and acquisitions, collaborations, partnerships, and joint ventures, make a competitive market dynamics.
As regulatory procedures become more stringent and competitive rivalry intensifies, new products must have a significant clinical advantage over existing products, in terms of safety and efficacy or the end result. This has led to a large number of head-to-head trials between key commercial products, such as Humira and Remicade, and new products or late-stage pipeline candidates. These trials determine the superiority of performance through a comparative analysis of several parameters.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2018 to 2026
North America, Europe, Asia Pacific, Latin America, MEA
Revenue forecast, company share, competitive landscape, growth factors and trends
U.S., Canada, U.K., Germany, Spain, France, Italy, Japan, China, India, South Korea, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global tumor necrosis factor inhibitor drugs market report on the basis of product, application, sales channel, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Application Outlook (Revenue, USD Million, 2014 - 2026)
Juvenile Idiopathic Arthritis
Sales Channel Outlook (Revenue, USD Million, 2014 - 2026)
Regional Outlook (Revenue, USD Million, 2014 - 2026)
Middle East & Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.